Rumors are swirling that Travis Kelce could retire from the NFL after the Kansas City Chiefs tight end came up short in his ...

During the recent period, Arrowhead (ARWR) signed and closed a potentially transformational licensing and collaboration agreement with Sarepta ...

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

The company projects plozasiran to generate $2 billion to $3 billion annually in the SHTG market alone, with Phase III studies (SHASTA-3, SHASTA-4, and MUIR 3) expected to complete enrollment this ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short ...

Owner, Paul Staico took over the bar after his father passed away and decided to turn it into Arrowhead East. It’s filled with everything Kansas City Chiefs: memorabilia, decor, jerseys ...

At close: February 6 at 12:56:43 PM GMT-3 ...

Myriad Uranium Corp. (CSE: M) (OTCQB: MYRUF) (FSE: C3Q) ("Myriad" or the "Company") is pleased to announce that it has issued ...